scholarly journals Real-world Propensity Score Comparison of Treatment Effectiveness of Peginterferon beta-1a vs. Subcutaneous Interferon beta-1a, Glatiramer Acetate, and Teriflunomide in Patients with Relapsing-Remitting Multiple Sclerosis

2021 ◽  
pp. 102935
Author(s):  
Anthony T Reder ◽  
Nancy Arndt ◽  
Cortnee Roman ◽  
Caroline Geremakis ◽  
Jason P Mendoza ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Propensity Score ◽  
Glatiramer Acetate ◽  
Real World ◽  
Interferon Beta ◽  
Treatment Effectiveness ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosis

2011 ◽  
Author(s):  
Loredana La Mantia ◽  
Alberto Vaona ◽  
Marco Rovaris ◽  
Francesco Berardo ◽  
Serena Frau ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

scholarly journals Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e042480
Author(s):  
Stefan Braune ◽  
Fabian Rossnagel ◽  
Heidi Dikow ◽  
Arnfin Bergmann
Keyword(s):  
Multiple Sclerosis ◽  
Real World ◽  
Treatment Effectiveness ◽  
Real World Data ◽  
World Data ◽  
Conversion Rates ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
The Impact

ObjectiveTo evaluate the impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany.DesignThis study employs real-world data captured in-time during clinical visits in 67 German neurology outpatient offices of the NeuroTransData (NTD) multiple sclerosis (MS) registry between 1 January 2010 and 30 June 2019, including 237 976 visits of 17 553 patients with RRMS. Adherence and clinical effectiveness parameters were analysed by descriptive statistics, time-to-event analysis overall and by disease-modifying therapies (DMTs) stratified by administration modes (injectable, oral and infusion). Three time periods were compared: 2010–2012, 2013–2015 and 2016–2018.ResultsBetween 2010 and 2018, an increasing proportion of patients with RRMS were treated with DMTs and treatment was initiated sooner after diagnosis of MS. Introduction of oral DMT temporarily induced higher readiness to switch. Comparing the three index periods, there was a continuous decrease of annualised relapse rates, less frequent Expanded Disability Status Scale (EDSS) progression and increasing periods without relapse, EDSS worsening and with stability of no-evidence-of-disease-activity 2 and 3 criteria, lower conversion rates to secondary progressive MS on oral and on injectable DMTs.ConclusionSparked by the availability of new mainly oral DMTs, RRMS treatment effectiveness improved clinically meaningful between 2010 and 2018. As similar effects were seen for injectable and oral DMTs more than for infusions, a better personalised treatment allocation in many patients is likely. These results indicate that there is an overall beneficial effect for the whole patient with MS population as a result of the greater selection of available DMTs, a benefit beyond the head-to-head comparative efficacy, resulting from an increased probability and readiness to individualise MS therapy.

Sign in / Sign up

Export Citation Format

Share Document